menu
    • menu
    [{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TD-0903","moa":"JAK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TD-0903","moa":"JAK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TD-0903","moa":"JAK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nezulcitinib","moa":"JAK","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Revefenacin","moa":"Muscarinic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Theravance Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ampreloxetine","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ampreloxetine","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ampreloxetine","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Divestment","leadProduct":"Fluticasone Furoate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Theravance Biopharma","amount2":1.55,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":1.55,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Theravance Biopharma \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Theravance Biopharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ampreloxetine","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Revefenacin","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Theravance Biopharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Theravance Biopharma

    Menu

    Theravance Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Revefenacin

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Theravance Biopharma Announces Results from Phase 4 YUPELRI® PIFR-2 Study in COPD Patients

                            Details : Yupelri (revefenacin) is a novel small molecule, M3 receptor inhibitor. It is under phase 4 clinical studies in patients with severe to very severe chronic obstructive pulmonary disease (COPD).

                            Brand Name : Yupelri

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 05, 2024

                            Lead Product(s) : Revefenacin

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ampreloxetine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Sym...

                            Details : TD-9855 (ampreloxetine) is an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).

                            Brand Name : TD-9855

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 09, 2023

                            Lead Product(s) : Ampreloxetine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ampreloxetine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium o...

                            Details : Ampreloxetine (TD-9855) is an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic nOH in patients with multiple system atrophy (MSA).

                            Brand Name : TD-9855

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 02, 2022

                            Lead Product(s) : Ampreloxetine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ampreloxetine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Theravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd Inter...

                            Details : Ampreloxetine (TD-9855) is an investigational, potent, long-acting, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).

                            Brand Name : TD-9855

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 25, 2022

                            Lead Product(s) : Ampreloxetine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluticasone Furoate,Umeclidinium Bromide,Vilanterol Trifenatate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Royalty Pharma

                            Deal Size : $1,550.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billio...

                            Details : The Company now anticipates it will approach breakeven cash flow in the second half of 2022 without the cash flows from its interest in GSK's Trelegy Ellipta (fluticasone furoate) royalties, driven by disciplined spending within R&D and the growth of YUP...

                            Brand Name : Trelegy Ellipta

                            Molecule Type : Small molecule

                            Upfront Cash : $1,100.0 million

                            July 13, 2022

                            Lead Product(s) : Fluticasone Furoate,Umeclidinium Bromide,Vilanterol Trifenatate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Royalty Pharma

                            Deal Size : $1,550.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ampreloxetine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Pati...

                            Details : Primary endpoint for ampreloxetine, an norepinephrine reuptake inhibitor was not statistically significant for overall population of patients which included patients with Parkinson's disease, pure autonomic failure and MSA.

                            Brand Name : TD-9855

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 04, 2022

                            Lead Product(s) : Ampreloxetine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Revefenacin

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study

                            Details : Enrollment of first patient in the Phase 4 PIFR-2 for YUPELRI® (revefenacin) is on the basis of continued investment in controlled clinical studies, that design to personalized treatment plans in order to make better-informed decisions for their COPD pa...

                            Brand Name : Yupelri

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 10, 2022

                            Lead Product(s) : Revefenacin

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nezulcitinib

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Theravance Biopharma Report Top-Line Results From Phase 2 Study of Nezulcitinib

                            Details : Nezulcitinib is an investigational, inhaled, lung-selective, pan-Janus kinase (JAK) inhibitor in development for hospitalized patients with confirmed COVID-19 associated acute lung injury and impaired oxygenation.

                            Brand Name : TD-0903

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 21, 2021

                            Lead Product(s) : Nezulcitinib

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nezulcitinib

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-0903

                            Details : First COVID-19 patient has been dosed in a Phase 2 study of TD-0903. TD-0903 is a lung-selective, nebulized Janus kinase inhibitor (JAKi) in development for the potential treatment of hospitalized patients with Acute Lung Injury (ALI) caused by COVID-19.

                            Brand Name : TD-0903

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 25, 2020

                            Lead Product(s) : Nezulcitinib

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Theravance Biopharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nezulcitinib

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Theravance Biopharma Announces First Subject Dosed In Phase 1 Study of TD-0903

                            Details : Theravance Biopharma received approval of TD-0903's initial Clinical Trial Application (CTA) in the United Kingdom (UK) for the Phase 1 study.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 23, 2020

                            Lead Product(s) : Nezulcitinib

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth